Wegovy (Semaglutide 2.4 mg) Constipation: Severity Grading Rubric and Management Guide

How common is constipation on Wegovy 2.4 mg?

In the three pooled double-blind trials of Wegovy 2.4 mg injection — 2,116 adults with obesity or overweight and 1,261 on placebo, treated for up to 68 weeks — constipation was reported by 24% and 11% respectively [1]. Among gastrointestinal reactions, only nausea (44%), diarrhea (30%) and vomiting (24%) were reported at the same or a higher rate [1].

The signal holds in pooled analyses. Nine randomized trials in adults with overweight or obesity and no diabetes, with 11,641 people on semaglutide and 10,479 on placebo, found higher odds of constipation with semaglutide than with placebo (odds ratio 2.43) [3]. A network meta-analysis of 39 studies covering 33,354 people in the same population found semaglutide and liraglutide were the GLP-1 receptor agonists linked to a significant increase in constipation risk [4].

Rates vary with product and population. In the two 72-week trials of the 7.2 mg dose, constipation was reported by 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo [1]. In adolescents aged 12 and older on 2.4 mg it was 6% versus 2% [1]. For the 25 mg Wegovy tablet, the label says reaction types and frequencies were similar to the injection table [1].

What the Wegovy label can and cannot distinguish

The label reports constipation as a single rate, 24% versus 11% [1], and reports a separate category called severe gastrointestinal adverse reactions: 4.1% on Wegovy injection versus 0.9% on placebo, and 2% versus 0% with the tablets [1]. That category is not itemised by symptom, so it does not say how much of it was constipation.

Below that sits the postmarketing list, which names ileus, intestinal obstruction and severe constipation including fecal impaction, and notes that frequency cannot be estimated from voluntary reports [1].

The label's pancreatitis warning describes persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and says to discontinue Wegovy if pancreatitis is suspected [1]. Two other label statements bear on bowel symptoms: Wegovy is not recommended in patients with severe gastroparesis, and semaglutide delays gastric emptying [1].

What helps constipation on Wegovy

A review of chronic constipation in general describes dietary fiber and, as appropriate, stimulant or osmotic laxatives as initial options, with other treatments such as intestinal secretagogues or prokinetic agents when those are insufficient [2]. That review is not specific to semaglutide.

Dose escalation and what the label says about tolerability

Wegovy is started at 0.25 mg weekly for weeks 1 to 4, then 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and maintenance from week 17 at 1.7 mg or 2.4 mg, with 2.4 mg recommended [1].

For adults, the Wegovy label lists 1.7 mg or 2.4 mg weekly as maintenance options and says a four-week delay in dose escalation can be considered when a dose is not tolerated [1].

In the pooled trials, 6.8% of adults on Wegovy 2.4 mg and 3.2% on placebo stopped treatment because of adverse reactions, and the label's list of the most common reasons names nausea, vomiting and diarrhea rather than constipation [1]. In STEP 1, 4.5% of semaglutide participants versus 0.8% on placebo discontinued for gastrointestinal events [5].

Is constipation worse at higher doses?

Not clearly, at least between 2.4 mg and 7.2 mg. Constipation was reported by 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo in the two 72-week trials [1]. Other reactions did climb with dose in the same trials: vomiting 22%, 16% and 6%, and dysesthesia 22%, 6% and 0% [1].

Adverse reaction rates from different trials cannot be directly compared, the label says [1].

Constipation or gastroparesis?

The label's gastroparesis statement is a restriction on use — Wegovy is not recommended in patients with severe gastroparesis — and the label does not state that semaglutide causes gastroparesis [1]. The label's mechanism statement is about the stomach emptying more slowly [1].